You are here

WinSanTor, Inc.

Company Information
Address
7220 Trade St Ste 370
San Diego, CA 92121-2380
United States



Information

UEI: VXEKFVKVN6Y5

# of Employees: 2


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Clinical investigation of topical delivery of a muscarinic receptor antagonist for the prevention of chemotherapy-induced peripheral neuropathy

    Amount: $2,000,000.00

    PROJECT SUMMARY Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating condition that afflicts 70% of cancer patients undergoing chemotherapy and limits the dose and duration of treatment ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  2. Submission of Investigational New Drug application to the Federal Drug Administration to support clinical development of topical pirenzepine for CIPN.

    Amount: $250,000.00

    PROJECT SUMMARY Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of many first-line chemotherapeutic drugs. Depending on the specific drug and dose regimen, CIPN can aff ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  3. Development of a topical fixed-dose combination drug for peripheral neuropathic pain.

    Amount: $699,491.00

    PROJECT SUMMARY An estimated 30 million people in the United States suffer from some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system. Th ...

    STTRPhase I2020Department of Health and Human Services National Institutes of Health
  4. Regeneration of Epidermal Nerves in Human Diabetic Neuropathy

    Amount: $2,981,077.00

    Project Summary/Abstract There is no FDA-approved therapy to prevent or reverse peripheral neuropathy, a condition that afflicts around 30 million people in the US and is often associated with diabete ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  5. Development of Pirenzepine for CIPN

    Amount: $1,997,420.00

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms ...

    STTRPhase II2018Department of Health and Human Services National Institutes of Health
  6. Development of Pirenzepine for CIPN

    Amount: $298,550.00

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathy CIPN is a debilitating complication that can arise from use of a number of chemotherapeutics and which limits both the dose and duration o ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  7. Assessment of chronic toxicity to support the use of topical pirenzepine for treating diabetic neuropathy

    Amount: $970,226.00

    PROJECT SUMMARY The objective of this SBIR Commercialization Readiness Program CRP project is to evaluate chronic toxicity of a new therapeutic for diabetic neuropathy in support of an IND submissio ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  8. Development of Pirenzepine for HIV SN

    Amount: $466,421.00

    PROJECT SUMMARY Over million people worldwide including million people in the USA are HIV positive HIV associated sensory neuropathy HIV SN is the most frequent neurological manifestation ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  9. Pre-Clinical Development of Topical Pirenzepine for Treating Diabetic Neuropathy

    Amount: $1,861,951.00

    DESCRIPTION provided by applicant The objective of this SBIR fast track project is to expediently advance pre clinical development of a new therapeutic for diabetic neuropathy Of the million Am ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  10. Pre-Clinical Development of Topical Pirenzepine for Treating Diapetic Neuropathy

    Amount: $371,908.00

    ? DESCRIPTION (provided by applicant): The objective of this SBIR fast-track project is to expediently advance pre-clinical development of a new therapeutic for diabetic neuropathy. Of the 25 mill ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government